News

Investing.com -- Citi told investors in a note Tuesday that the recent pullback in semiconductor stocks looks like a buying opportunity, arguing that fears of an AI spending slowdown are overdone.

Citigroup (NYSE:C) Chief Financial Officer Gonzalo Luchetti said the bank expects full-year return on tangible common equity, or ROTCE, to finish slightly above the high end of its previously stated 10% to 11% range, citing continued momentum across its markets, banking, services and consumer busine

Can C's transformation, cost cuts and capital returns drive further upside despite its 29.3% six-month rally? Let us find out.

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental breast cancer drug camizestrant has failed a late-stage trial, though analysts at Citi say the setback does little to dent the company's prospects. Citi kept its 'buy' rating and £178 target price on the FTSE 100 pharmaceuticals group,...

Over the past six months, Citigroup has been a great trade, beating the S&P 500 by 14.1%. Its stock price has climbed to $138.48, representing a healthy 26.8% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

JPM, GS, C and MS are four investment bank giants that have rallied more than 20% in six months while trading at attractive valuations.

Citi just slapped a Buy rating on UiPath with a target nearly 70% above the current price, yet shares keep falling. Here is what the bull and bear camps are fighting over ahead of a high-stakes investor day that could flip the narrative.

A robust outlook for Corporate America is helping underpin US stocks as inflation risks mount.

Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination...

Here is how Citigroup (C) and Federal Agricultural Mortgage (AGM) have performed compared to their sector so far this year.

Citigroup has outperformed the Financial sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

Howmet Stock Plunges on SpaceX Production Shift as Citi Spots a Buying Opportunity

One analyst thinks the stock’s brutal slide is not the result of bad business.

JPMorgan's rally reflects strong NII, IB and trading growth, though rising costs and valuation remain key factors to watch. Is the stock worth buying?

Bank of America's AI push and branch expansion are boosting efficiency. However, persistent expense pressure could cloud the case for fresh investment.

Citi said that it had added an "upside 90-day catalyst watch" on Oracle while keeping a ‘Buy’ rating on the shares with a $330 price target.

The $330 target promises a dramatic recovery, but Oracle's negative free cash flow keeps the burden of proof unusually high.

Oracle Shares Gain After Citi Sees Potential Turnaround in Cloud Growth

Does GS's earnings momentum, fee-driven strategy and growth visibility give it the edge over C despite a higher valuation? Let us find out.

MS outpaces peers with a 45.1% share price gain, but trading cyclicality, rising expenses and a premium valuation could limit further upside.

Based on the average brokerage recommendation (ABR), Citigroup (C) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest of 2026 and how best to position their portfolios.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks The good news is that the latest earning

Santander completes Webster acquisition to expand its U.S. scale and diversification. Can the enlarged franchise unlock stronger growth and profitability?

Investing.com -- Citi maintained its overweight rating on equities in a note Friday, telling investors it would use any weakness ahead of the U.S. midterm elections to add exposure.

Alibaba Group Holding Ltd. is reclaiming its place as one of investors’ favorite Chinese technology stocks, on bets it can beat rivals in the combative artificial intelligence market.

JPMorgan Chase & Co. strategists warned that markets may view the US Treasury’s surprise effort to curb long-term borrowing costs as lacking credibility, potentially pushing up term premium and yields over time.

Here is how Acadian Asset Management (AAMI) and Citigroup (C) have performed compared to their sector so far this year.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the...

Investing.com -- Citi upgraded Bath & Body Works to Buy from Neutral ahead of the retailer’s second-quarter results next week, citing expectations for an earnings beat, a depressed stock price and potential upside from energy prices and tariff refunds. This combination of factors "creates a very attractive risk/reward" heading into the print, the bank’s analysts said.

Bath & Body Works (NYSE:BBWI) shares gained 2. 6% in pre-market trading on Tuesday after Citi upgraded the specialty retailer to Buy from Neutral, arguing that the stock’s steep decline following its previous earnings update has created a more attractive risk-reward profile.